Montreal, Canada: May 16, 2025 -- Altis Labs, Inc. (“Altis”) is announcing results presented at The International Society for Health Economics and Outcomes Research (ISPOR) Conference 2025: in AstraZeneca’s randomized controlled Phase 3 MYSTIC trial in metastatic non-small cell lung cancer, real-world digital twins identified by Altis’ IPRO models replicated control arm outcomes. 

Altis applied MYSTIC’s eligibility criteria to its multimodal real-world data to identify historical patients treated with relevant standard-of-care (SOC) treatment. AI models processed the real-world baseline CT scans and quantified thousands of spatial imaging biomarkers representing total tumor burden, body composition, and other prognostic features. Using baseline imaging characteristics of each MYSTIC subject, “matching” rwDTs were identified to generate an External Control Arms (ECAs). 

AstraZeneca independently evaluated the survival outcomes of the ECAs and compared them to the MYSTIC trial arms, concluding that the ECAs successfully emulated the actual control arm and yielded consistent treatment effect estimates.

Access the abstract and poster here.

About Altis Labs

Altis Labs is the computational imaging company accelerating clinical trials with AI. 

Altis has created the industry's largest real-world Imaging, Clinical, and Outcomes database – comprising over 210 million cancer patient images linked to associated demographic, diagnostic, molecular, treatment, and survival information. Deep learning models trained on rwICO can generate profound insights beyond tumor measurements that make up reductionist criteria like RECIST 1.1, yielding greater association with overall survival. 

Top 20 biopharma sponsors apply our deep learning models to their clinical trial imaging data to unlock powerful insights. Our models instantaneously generate Imaging-based Prognostication (IPRO) scores and thousands of Spatial Imaging Biomarkers (SIBs) from each scan, which Sponsors can combine for analysis with other data modalities such as ctDNA. These insights are being explored by clinical development teams to quantify treatment effects earlier in order to design more successful clinical trials. 

Our multi-disciplinary team is on a mission to help get the most effective novel treatments to patients sooner. Altis is proudly headquartered in Toronto, ON.

‍